Meeting News CoverageVideo

VIDEO: HSCT remains important option for younger patients with multiple myeloma

ORLANDO, Fla. — A study presented at the ASH Annual Meeting showed hematopoietic stem cell transplantation remains an important option for younger patients with de novo multiple myeloma. However, Paul G. Richardson, MD, suggests “one size does not necessarily fit all” and exact timing can be a matter of choice.

ORLANDO, Fla. — A study presented at the ASH Annual Meeting showed hematopoietic stem cell transplantation remains an important option for younger patients with de novo multiple myeloma. However, Paul G. Richardson, MD, suggests “one size does not necessarily fit all” and exact timing can be a matter of choice.

    See more from ASH Annual Meeting and Exposition